ArticleJournal of viral hepatitis2025
Reduced Predictive Performance of the FIB-4 Index in Chronic Hepatitis B Patients With Concurrent Metabolic Dysfunction-Associated Liver Disease.
Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic value of LPRI for assessing advanced liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.BMC gastroenterology · 2026Article
- Reduced Predictive Performance of the FIB-4 Index in Chronic Hepatitis B Patients With Concurrent Metabolic Dysfunction-Associated Liver Disease.Journal of viral hepatitis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of chronic hepatitis B (CHB) and metabolic dysfunction-associated liver disease (MASLD) gained recognition, but the diagnostic performance of non-invasive markers regarding it remains underexplored. This study aimed to evaluate the utility of the FIB-4 index for fibrosis prediction in CHB patients and investigate its performance in the distinct subgroup of CHB-MASLD. A prospective study from 2021 to 2022 included 109 CHB and 64 CHB-MASLD patients. All underwent liver stiffness measurement via elastography and FIB-4 calculation. MASLD criteria were defined, creating CHB-alone and CHB-MASLD groups. FIB-4 values were compared to the liver stiffness measurements. Statistical analyses included t-tests, ROC curves, and correlation assessments. No significant age, gender, or ethnicity differences were observed between the CHB and CHB-MASLD groups. CHB-MASLD patients exhibited higher BMI, dysglycemia, and dyslipidemia. HBeAg negativity and nucleoside/tide treatment rates were comparable. FIB-4 and APRI scores were elevated in CHB-MASLD. ROC analysis revealed an AUC of 0.86 for FIB-4 in the CHB group, with an optimal cutoff of 1.95. Subgroup analysis by BMI showed consistent FIB-4 performance. In the CHB-MASLD group, the ROC curve showed an AUC of 0.61 (p = 0.12), indicating non-significance. Our study affirms FIB-4's robust performance in predicting fibrosis in CHB patients across varied BMI profiles. Yet, challenges surface when applying FIB-4 to those with concurrent CHB and MASLD. These limitations stress the urgency of refined fibrosis prediction tools, essential for navigating the complex interplay of viral and metabolic factors in the CHB-MASLD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.